A Study of Pembrolizumab in Patients With Relapsed Or Metastatic Osteosarcoma Not Eligible for Curative Surgery
Status:
Terminated
Trial end date:
2019-01-31
Target enrollment:
Participant gender:
Summary
This is a phase II, single arm, open-label, interventional trial of pembrolizumab (MK-3475)
in patients with osteosarcoma who have experienced disease relapse or progression after at
least one line of systemic treatment, and who are not eligible for curative surgery.